SMS Pharma Q1 FY27 Results: Profit ₹211 Crore; MD Re-appointed
SMS Pharmaceuticals Limited reported Q1 FY27 results with standalone net profit at ₹21.13 crore and consolidated net profit at ₹20.91 crore. The Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for five years from October 1, 2026. A loan of up to ₹50 crore to a subsidiary was also approved. The 38th AGM is scheduled for September 23, 2026.
The financial results show modest growth, and the re-appointment of the MD provides management stability. The loan to the subsidiary is a strategic move but its impact is contingent on the subsidiary's performance.
The company reported growth in net profit for both standalone and consolidated results compared to the previous year. The re-appointment of the Managing Director for a long term signals stability and confidence.
SMS Pharmaceuticals Limited announced its financial results for the first quarter ended June 30, 2026. The company's Board of Directors, in a meeting held on July 31, 2026, approved the un-audited standalone and consolidated financial results.
The standalone net profit for the quarter stood at ₹2,113.26 lakhs (₹21.13 crore), an increase from ₹1,820.75 lakhs (₹18.21 crore) in the corresponding quarter of the previous year. Total income from operations for the quarter was ₹20,696.49 lakhs (₹206.96 crore).
Consolidated net profit for the quarter was ₹2,090.90 lakhs (₹20.91 crore), compared to ₹2,049.05 lakhs (₹20.49 crore) in the same period last year. Consolidated total income from operations was ₹20,696.49 lakhs (₹206.96 crore).
In a significant management update, the Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for a term of five years, effective from October 1, 2026, to September 30, 2031, subject to shareholder approval.
The company also approved a loan of up to ₹50 crore to its subsidiary, SMS Peptides Private Limited, subject to shareholder approval.
The 38th Annual General Meeting (AGM) is scheduled for September 23, 2026. The Register of Members and Share Transfer Books will be closed from September 17 to September 23, 2026, for the AGM. The record date for determining eligibility for dividend (if approved at the AGM) for the financial year 2025-26 has been fixed as September 16, 2026.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.